The use of Biofeedback and electrostimulation therapy in patients with low anterior resection syndrome after rectal carcinoma and rectal resection to enhance quality of life and fecal continence

The use of Biofeedback and electrostimulation therapy in patients with low anterior resection syndrome after rectal carcinoma and rectal resection to enhance quality of life and fecal continence - BESTE LEBENSQUALITÄT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00011765

Enrollment

Registered

2017-03-10

Start date

2017-04-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Carcinoma Fecal incontinence C20 R15

Interventions

Group 1: All patients with rectal carcinoma that underwent rectal resection (anterior or low anterior resection ) between 1999 and 2017 in Agatharied Hospital and have been diagnosed with fecal incont

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: patients with rectal carcinoma who underwent anterior or low anterior resection in Aagatharied Hospital between 1999 and 2017 Fecal Incontinence after Parks (I-III) Total mesorectal Excision in patients with low and middle rectal cancer ( 0-6 and 6-12 cm from the anal verge) or partial mesorectal excision in patients with rectal carcinom 12-16cm from the anal verge. Earliest time for evalutation:6 weeks after last surgery Loop ileostomy has to have been reversed The Patient has to be able to cognitive and physically perform Biofeedback und middle frequent electrostimulation therapy.

Exclusion criteria

Exclusion criteria: Participation in another interventionel study Patients with local recurrence or Progress of the cancer Patients with vulnerable rectum mucosa, inflammatory changes or Stenosis in the rectum Patients under 18 Pregnancy Patients that are not mentally or physically capable of consenting to the study

Design outcomes

Primary

Measure	Time frame
Improvement of fecal incontinence in the CCS Score (Fecal incontinence Score), measured 6 weeks, 3,6 and 12 months after beginn of therapy	—

Secondary

Measure	Time frame
LARS Score ( Low anterior resection Syndrome Score) FiQuOL ( Fecal Incontinence Quality of Life) Anal manometry Tumor classification UICC Quality of TME (total mesorectal excision) Mercury Hight of anastomosis Complications of surgery ( Clavien Dindo ) Time between surgery and begin of therapy Neoadjuvant Radiochemotherapy	—

Countries

Germany

Contacts

Public ContactSusanne Rogers

Allgemein-, Viszeral-, GefässchirurgieKrankenhaus Agatharied

susanne.rogers@khagatharied.de08026-3932444

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026